PMID- 35645118
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20220603
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 18
IP  - 2
DP  - 2022 Apr
TI  - Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in 
      patients with metastatic or recurrent cervical cancer: An open-label, phase 2 
      trial.
PG  - 482-487
LID - 10.4103/jcrt.jcrt_1851_21 [doi]
AB  - AIMS: This study evaluates the safety and preliminary antitumor efficacy of 
      camrelizumab with albumin-binding paclitaxel and cisplatin as first-line therapy 
      for patients with recurrent or metastatic cervical carcinoma. METHODS AND 
      MATERIAL: In this phase 2, open-label, prospective study, 35 patients with 
      recurrent or metastatic cervical carcinoma with no previous systemic chemotherapy 
      were included. The patients were treated with a maximum of six cycles of 
      camrelizumab on day 1, albumin-binding paclitaxel, and carboplatin on day 2, 
      every 3 weeks, followed by camrelizumab once every 3 weeks. The primary outcomes 
      were objective response rate (ORR) and disease control rate (DCR). Secondary 
      outcomes were duration of response (DoR) and safety. Furthermore, 27 patients 
      were included in the per-protocol set for efficacy analysis, whereas for the 
      safety analysis, all patients were included. RESULTS: The median follow-up was 
      4.53 months, and the complete response, partial response, and stable disease were 
      also achieved in 4 (14.81%), 6 (22.22%), and 13 (48.15%) patients. The ORR and 
      DCR were 40.00% (95% confidence interval: 21.13-61.33%) and 92.00% 
      (73.97-99.01%), respectively. The median DoR was 6.70 months. In addition, the 
      most common adverse events (AEs) were reactive cutaneous capillary endothelial 
      proliferation (RCCEP) (23, 65.71%), gastrointestinal reaction (8, 22.86%), and 
      fever (8, 22.86%). Grade 3 AEs included 5 (14.29%) myelosuppression, and grade 4 
      AEs included 1 (2.86%) RCCEP and 1 (2.86%) bladder inflammation. CONCLUSIONS: 
      Combination therapy of camrelizumab and albumin-bound paclitaxel and carboplatin 
      shows promising efficacy and manageable toxicities in patients with recurrent or 
      metastatic cervical cancer.
FAU - Zhang, Xiaoling
AU  - Zhang X
AD  - Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, Shandong, People's Republic of China.
FAU - Chen, Jinlong
AU  - Chen J
AD  - Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, Shandong, People's Republic of China.
FAU - Liu, Naifu
AU  - Liu N
AD  - Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, Shandong, People's Republic of China.
FAU - Wang, Qian
AU  - Wang Q
AD  - Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, Shandong, People's Republic of China.
FAU - Wu, Qian
AU  - Wu Q
AD  - Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, Shandong, People's Republic of China.
FAU - Gao, Fufeng
AU  - Gao F
AD  - Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, Shandong, People's Republic of China.
FAU - Sang, Yingchun
AU  - Sang Y
AD  - Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, 
      Shandong First Medical University and Shandong Academy of Medical Sciences, 
      Jinan, Shandong, People's Republic of China.
FAU - Wang, Ping
AU  - Wang P
AD  - Department of Gynecology, People's Hospital of Zouping City, Binzhou, Shandong, 
      People's Republic of China.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Albumin-Bound Paclitaxel)
RN  - 0 (Albumins)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 73096E137E (camrelizumab)
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - *Albumin-Bound Paclitaxel
MH  - Albumins
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Carboplatin
MH  - Chronic Disease
MH  - Female
MH  - Humans
MH  - Paclitaxel/therapeutic use
MH  - Prospective Studies
MH  - *Uterine Cervical Neoplasms/pathology
OTO - NOTNLM
OT  - Albumin-bound paclitaxel
OT  - camrelizumab (shr-1210)
OT  - carboplatin
OT  - cervical cancer
OT  - prospective study
COIS- None
EDAT- 2022/06/02 06:00
MHDA- 2022/06/07 06:00
CRDT- 2022/06/01 11:05
PHST- 2022/06/01 11:05 [entrez]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
AID - JCanResTher_2022_18_2_482_345533 [pii]
AID - 10.4103/jcrt.jcrt_1851_21 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2022 Apr;18(2):482-487. doi: 10.4103/jcrt.jcrt_1851_21.